

News

London, UK, 27 September 2007, Curidium Medica plc, (LSE: CUR) announces interim results.

Curidium Medica plc

("Curidium Medica", the "Group" or the "Company")

Interim report for the period ended 30th June 2007

Operational Highlights

	6 months to 30 June 2007 (unaudited)	6 months to 30 June 2006 (unaudited)	Year ended 31 December 2006 (audited)
Research and development expenditure	£177,292	£64,965	£304,712
Group operating loss	£552,982	£120,043	£976,558
Loss on ordinary activities before tax	£532,614	£120,043	£945,036
Basic and fully diluted loss per share	0.10 p	0.05 p	0.24 p
Cash out flow from operating activities	£448,622	£87,785	£627,291

Chairman's Statement

The first half of 2007 was a period of significant progress in establishing Curidium Medica in the growing area of Personalised Medicine. One of the biggest challenges in medicine today is the selection, by the doctor, of those specific treatments that are most likely to work best in the individual patient. Governments, healthcare payers, and patient advocacy groups are increasingly intolerant of the prescription of drugs that are not or only marginally effective in large groups of patients. Furthermore, the pharmaceutical industry is urgently seeking tools that will allow them to develop more drugs more successfully; in fact, the high number of failures of drugs in development has in part fuelled the burgeoning healthcare costs that we all currently face.

Curidium Medica believes that Homomatrix[®], the Company's core technology, could be one of the tools that can help address the challenges described above. Thus far, in 2007, Homomatrix[®] was fine-tuned, automated and subsequently applied to three different datasets in schizophrenia/bipolar disorder. This disease is one of high medical need that urgently requires safe and effective ("SZ/BP") treatments. The outcome of this effort was the identification of four highly statistically different subgroups of patients within SZ/BP disorder. The identification of these subgroups may offer the potential of better selection of patient treatments as well as the identification of novel drugs targeting one or more of the subgroups. Establishing the clinical usefulness of the Company's findings in the area of SZ/BP disorder also took an important step forward with the subsequent identification of PsychINDx[™] a blood test that could potentially be used by doctors to aid in the identification of the subgroup to which a SZ/BP disorder patient belongs. Importantly, the successful outcome of its first Homomatrix[®] application leads the Company to believe that the Homomatrix[®] technology may also be successfully applied to other heterogeneous and difficult to treat diseases potentially leading to the identification of 1) diagnostics to differentiate between distinct patient subgroups 2) novel drug targets and 3) companion diagnostics and related targeted treatments for one or more of the patient subgroups. Curidium Medica aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas.

The area of personalised medicine will continue to becoming increasingly important for all of the stakeholders within the pharmaceutical industry and the practice of medicine. Approaches to develop personalised medicine will undoubtedly continue to use different strategies to try to improve the selection patients. The goal is to identify those patients that are most likely to respond best to a specific treatment through the use of companion diagnostics and/or novel treatments. There are significant resources being brought to bear in this area and companies small and large are using a myriad of approaches to rise to the challenge. Curidium Medica's Homomatrix[®] and PsychINDx[™] and the Company's future efforts in other disease indications may potentially contribute significantly to this important area. Curidium intends to develop better medicines through application of its technology via strategic partnerships and in-licensed therapeutics. To this end, the Company was pleased to announce, on 30 July 2007, that it placed 100,000,000 0.1 pence ordinary shares with strategic investors at a price of 2.5 pence per share resulting in gross proceeds of £2,500,000 to the Company. This investment has significantly strengthened the Company's balance sheet and will allow us to further develop our products and markets.

Gosse B. Bruinsma, MD
Chairman
27th September 2007

Financial Statements

The consolidated financial statements are issued in the name of Curidium Medica plc, but they are a continuance of the financial statements of Curidium Limited. As such the comparative results for the period ending 30 June 2006 and balances as at 30 June 2006 are those of Curidium Limited.

CONSOLIDATED INCOME STATEMENT For the six months ended 30 June 2007

	6 months to 30 June 2007 (unaudited)	6 months to 30 June 2006 (unaudited)	Year ended 31 December 2006 (audited)
	£	£	£
Research and Development	(177,292)	(64,965)	(304,712)
Administrative expenses	(378,690)	(66,709)	(683,477)
Other operating income	3,000	11,631	11,631
<i>(Loss) from operations</i>	(552,982)	(120,043)	(976,558)
Interest receivable	20,368	-	31,522
Loss on ordinary activities before tax	(532,614)	(120,043)	(945,036)
Tax		14,030	60,730
Loss for the period attributable to shareholders	(532,614)	(106,013)	(884,306)

The Group's operating losses arise from continuing operations.

There were no recognised gains or losses other than those recognised in the income statement above.

LOSS PER SHARE

	6 months to 30 June 2007 (unaudited)	6 months to 30 June 2006 (unaudited)	Year ended 31 December 2006 (audited)
	pence	pence	pence
Loss per share			
From continuing operations			
Basic	0.10	0.05	0.24
Diluted	0.10	0.05	0.24

CONSOLIDATED BALANCE SHEET
As at 30 June 2007

	as at 30 June 2007 (unaudited)	as at 30 June 2006 (unaudited)	as at 31 December 2006 (audited)
	£	£	£
ASSETS			
Non-current assets			
Goodwill	1,097,542	-	1,097,542
Property, plant and equipment	7,837	3,243	6,112
	1,105,379	3,243	1,103,654
Current assets			
Trade and other receivables	93,029	38,099	113,493
Cash and cash equivalents	1,290,847	1,956	1,722,527
	1,383,876	40,055	1,836,020
Total assets	2,489,255	43,298	2,939,674
Current liabilities			
Trade and other payables	(187,459)	(90,757)	(229,486)
	(187,459)	(90,757)	(229,486)
Net current assets (liabilities)	1,196,417	(50,702)	1,606,534
Non-current liabilities			
	-	-	-
Total liabilities	(187,459)	(90,757)	(229,486)
Net assets (liabilities)	2,301,796	(47,459)	2,710,188
EQUITY			
Share Capital	4,050,179	390,016	3,925,956
Accumulated deficit	(1,748,383)	(437,475)	(1,215,768)
Equity attributable to equity holders of the parent Company	2,301,796	(47,459)	2,710,188

CONSOLIDATED CASH FLOW INFORMATION
SUMMARY CASH FLOW STATEMENT

	6 months to 30 June 2007 (unaudited)	6 months to 30 June 2006 (unaudited)	Year ended 31 December 2006 (audited)
	£	£	£
OPERATING ACTIVITIES			
Operating loss	(552,982)	(120,043)	(976,558)
Share based payments	124,223	-	165,573
Depreciation	1,700	561	1,961
(Increase) / decrease in receivables	20,464	4,896	(23,797)
Increase / (decrease) in payables	(42,027)	26,801	205,530
NET CASH OUTFLOW FROM OPERATING ACTIVITIES	(448,622)	(87,785)	(627,291)
INVESTING ACTIVITIES			
Interest received	20,368	-	31,522
Purchases of property, plant and equipment	(3,426)	(2,449)	(6,719)
Acquisition of subsidiary including cash balances acquired	-	-	770,826
NET CASH USED IN INVESTING ACTIVITIES	16,942	(2,449)	795,629
FINANCING ACTIVITIES			
Loans received	-	40,000	-
Proceeds from issue of share capital	-	-	1,502,000
NET CASH FROM FINANCING ACTIVITIES	-	40,000	1,502,000
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	(431,680)	(50,234)	1,670,338
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	1,722,527	52,189	52,189
CASH AND CASH EQUIVALENTS AT END OF PERIOD	1,290,847	1,955	1,722,527

Notes to the interim statements

For the six months ended 30th June 2006

1) SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRSs). The financial statements have been prepared on the historical cost basis. The principal accounting policies adopted are set out below.

Basis of Consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries) made up to 30th June and 31st December each year. Control is achieved where the Company has the power to govern the financial and operating policies of an investee entity so as to obtain benefits from its activities.

On acquisition, the assets and liabilities and contingent liabilities of a subsidiary are measured at their fair values at the date of acquisition. Any excess of the cost of acquisition over the fair values of the identifiable net assets acquired is recognised as goodwill. Any deficiency of the cost of acquisition below the fair values of the identifiable net assets acquired (i.e. discount on acquisition) is credited to profit and loss in the period of acquisition. The interest of minority shareholders is stated at the minority's proportion of the fair values of the assets and liabilities recognised. Subsequently, any losses applicable to the minority interest in excess of the minority interest are allocated against the interests of the parent.

All intra-group transactions, balances, income and expenses are eliminated on consolidation.

On 5th July 2006 the shareholders approved the business combination of the Company and Curidium Limited, under the AIM rules and IFRS this transaction meets the criteria of a Reverse Takeover. The consolidated accounts have therefore been presented under the Reverse Accounting principles of IFRS 3 and show comparatives for Curidium Limited.

The consolidated financial statements prepared following the reverse are issued in the name of Curidium Medica plc, but they are a continuance of the financial statements of Curidium Limited. Therefore the assets and liabilities of Curidium Limited have been recognised and measured in these consolidated financial statements at their pre-combination carrying values. The retained earnings and other equity balances recognised in these consolidated financial statements are the retained earnings and other equity balances of Curidium Limited immediately before the business combination.

The amount recognised as issued equity instruments in these consolidated financial statements has been determined by adding the issued equity of Curidium Limited immediately before the business combination to the cost of the consideration. However, the equity structure appearing in these consolidated financial statements (the number and type of equity instruments issued) reflect the equity structure of Curidium Medica plc, including equity instruments issued by the Company to effect the consolidation.

Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by the Group.

Share-based Payments

The Group has applied the requirements of IFRS 2 Share-based Payments. In accordance with the transitional provisions, IFRS 2 has been applied to all grants of equity instruments after 7th November 2002 that were unvested as of 1st January 2005.

The Group issues equity-settled and cash-settled share-based payments to certain employees. Equity-settled share-based payments are measured at fair value at the date of grant. The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Group's estimate of shares that will eventually vest.

Fair value is measured by use of a binomial model. The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions, and behavioural considerations.

A liability equal to the portion of the goods or services received is recognised at the current fair value determined at each balance sheet date for cash-settled share-based payments.

2) LOSS PER SHARE

Loss per share data is based on the consolidated loss using reverse accounting principals and the weighted average number of shares in issue of the Parent Company.

	6 months to 30 June 2007 (unaudited)	6 months to 30 June 2006 (unaudited)	Year ended 31 December 2006 (audited)
	£	£	£
Loss for the purposes of basic and diluted loss per share being net loss attributable to equity holders of the parent	(532,614)	(106,013)	(884,306)

Number of shares

	6 months to 30 June 2007 (unaudited)	6 months to 30 June 2006 (unaudited)	Year ended 31 December 2006 (audited)
Weighted average number of ordinary shares for the purposes of basic and diluted earnings per share	511,083,758	233,428,062	372,255,910

The share options are anti-dilutive as they decrease the loss per share.

The denominators for the purposes of calculating both basic and diluted earnings per share have been adjusted to reflect the issue of shares in July 2006 associated with the acquisition of Curidium Limited.

3) SHARE CAPITAL

Share Capital for Curidium Medica plc is set out in the following table:

	as at 30 June 2007 (unaudited)	as at 30 June 2006 (unaudited)	as at 31 December 2006 (audited)
	Number	Number	Number
<i>Authorised:</i>			
Ordinary shares of 0.1p each	860,000,000	260,000,000	860,000,000
Deferred shares of 24p each	40,000,000	40,000,000	40,000,000
Deferred shares of 0.9p each	60,000,000	60,000,000	60,000,000
	960,000,000	360,000,000	960,000,000

	as at 30 June 2007 (unaudited)	as at 30 June 2006 (unaudited)	as at 31 December 2006 (audited)
	Number	Number	Number
<i>Alloted, called up and fully paid:</i>			
Ordinary shares of 0.1p each	457,811,392	180,155,696	457,811,392
Deferred shares of 24p each	17,866,670	17,866,670	17,866,670
Deferred shares of 0.9p each	35,405,696	35,405,696	35,405,696
	511,083,758	233,428,062	511,083,758

	as at 30 June 2007 (unaudited)	as at 30 June 2006 (unaudited)	as at 31 December 2006 (audited)
	£	£	£
<i>Authorised:</i>			
Ordinary shares of 0.1p each	860,000	260,000	860,000
Deferred shares of 24p each	9,600,000	9,600,000	9,600,000
Deferred shares of 0.9p each	540,000	540,000	540,000
	11,000,000	10,400,000	11,000,000

	as at 30 June 2007 (unaudited)	as at 30 June 2006 (unaudited)	as at 31 December 2006 (audited)
	£	£	£
<i>Alloted, called up and fully paid:</i>			
Ordinary shares of 0.1p each	457,811	180,156	457,811
Deferred shares of 24p each	4,288,001	4,288,001	4,288,001
Deferred shares of 0.9p each	318,651	318,651	318,651
	5,064,463	4,786,808	5,064,463

4) STATEMENT OF CHANGES IN EQUITY

	£
Balance as at 1 January 2007	2,710,188
Share options granted	124,222
Net loss for the period	<u>(532,614)</u>
Balance at 30 June 2007	<u><u>2,301,796</u></u>

Equity comprises share capital, share premium and retained earnings.

5) POST BALANCE SHEET EVENT

On the 30 July, 2007 the Company announced that it placed 100,000,000 0.1 pence ordinary shares with strategic investors at a price of 2.5 pence per share resulting in gross proceeds of £2,500,000 to the Company.

The proceeds of the placing will be used to expand the Company's business and product development activities including the opportunities that have come with the recent discovery of Curidium's proprietary PsychINDx™ test.

The new shares were admitted to trading on AIM on 1 August 2007. Following this transaction the Company had 557,811,392 ordinary shares in issue. As part of the transaction, the lead investor received options to buy 5,000,000 ordinary shares at 2.5 pence exercisable over a period of 5 years.

6) COPIES OF INTERIM REPORT

The Interim report is available to view and download from the Companies website at www.curidium.com. If shareholders would like a hardcopy of the interim report they should contact the Company Secretary, Rob Smith, on 020 7554 8790.